Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study
- PMID: 29792314
- PMCID: PMC6190010
- DOI: 10.1136/bmj.k1786
Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study
Abstract
Objective: To investigate whether adults with atopic eczema are at an increased risk of cardiovascular disease and whether the risk varies by atopic eczema severity and condition activity over time.
Design: Population based matched cohort study.
Setting: UK electronic health records from the Clinical Practice Research Datalink, Hospital Episode Statistics, and data from the Office for National Statistics, 1998-2015.
Participants: Adults with a diagnosis of atopic eczema, matched (on age, sex, general practice, and calendar time) to up to five patients without atopic eczema.
Main outcome measures: Cardiovascular outcomes (myocardial infarction, unstable angina, heart failure, atrial fibrillation, stroke, and cardiovascular death).
Results: 387 439 patients with atopic eczema were matched to 1 528 477 patients without atopic eczema. The median age was 43 at cohort entry and 66% were female. Median follow-up was 5.1 years. Evidence of a 10% to 20% increased hazard for the non-fatal primary outcomes for patients with atopic eczema was found by using Cox regression stratified by matched set. There was a strong dose-response relation with severity of atopic eczema. Patients with severe atopic eczema had a 20% increase in the risk of stroke (hazard ratio 1.22, 99% confidence interval 1.01 to 1.48), 40% to 50% increase in the risk of myocardial infarction, unstable angina, atrial fibrillation, and cardiovascular death, and 70% increase in the risk of heart failure (hazard ratio 1.69, 99% confidence interval 1.38 to 2.06). Patients with the most active atopic eczema (active >50% of follow-up) were also at a greater risk of cardiovascular outcomes. Additional adjustment for cardiovascular risk factors as potential mediators partially attenuated the point estimates, though associations persisted for severe atopic eczema.
Conclusions: Severe and predominantly active atopic eczema are associated with an increased risk of cardiovascular outcomes. Targeting cardiovascular disease prevention strategies among these patients should be considered.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Figures
Comment in
-
Revisiting atopic dermatitis and cardiovascular disease.Br J Dermatol. 2018 Sep;179(3):801-802. doi: 10.1111/bjd.16891. Epub 2018 Jul 5. Br J Dermatol. 2018. PMID: 29917227 No abstract available.
Similar articles
-
Atopic eczema in adulthood and mortality: UK population-based cohort study, 1998-2016.J Allergy Clin Immunol. 2021 May;147(5):1753-1763. doi: 10.1016/j.jaci.2020.12.001. Epub 2021 Jan 27. J Allergy Clin Immunol. 2021. PMID: 33516523 Free PMC article.
-
Atopic eczema and fracture risk in adults: A population-based cohort study.J Allergy Clin Immunol. 2020 Feb;145(2):563-571.e8. doi: 10.1016/j.jaci.2019.09.015. Epub 2019 Nov 19. J Allergy Clin Immunol. 2020. PMID: 31757515 Free PMC article.
-
Migraine and risk of cardiovascular diseases: Danish population based matched cohort study.BMJ. 2018 Jan 31;360:k96. doi: 10.1136/bmj.k96. BMJ. 2018. PMID: 29386181 Free PMC article.
-
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2022 Feb 24;2(2):CD013556. doi: 10.1002/14651858.CD013556.pub2. Cochrane Database Syst Rev. 2022. PMID: 35199850 Free PMC article. Review.
-
Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses.Health Technol Assess. 2021 Nov;25(71):1-174. doi: 10.3310/hta25710. Health Technol Assess. 2021. PMID: 34847987 Review.
Cited by
-
Cardiodermatology: the heart of the connection between the skin and cardiovascular disease.Nat Rev Cardiol. 2024 Nov 13. doi: 10.1038/s41569-024-01097-9. Online ahead of print. Nat Rev Cardiol. 2024. PMID: 39537837 Review.
-
Cohort studies on 71 outcomes among people with atopic eczema in UK primary care data.Nat Commun. 2024 Nov 6;15(1):9573. doi: 10.1038/s41467-024-54035-1. Nat Commun. 2024. PMID: 39505873 Free PMC article.
-
Generalized Pustular Psoriasis and Systemic Organ Dysfunctions.Int J Mol Sci. 2024 Jun 6;25(11):6270. doi: 10.3390/ijms25116270. Int J Mol Sci. 2024. PMID: 38892457 Free PMC article. Review.
-
Characterization of High and Low IFNG-Expressing Subgroups in Atopic Dermatitis.Int J Mol Sci. 2024 Jun 3;25(11):6158. doi: 10.3390/ijms25116158. Int J Mol Sci. 2024. PMID: 38892346 Free PMC article.
-
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.Am J Clin Dermatol. 2024 Jul;25(4):639-654. doi: 10.1007/s40257-024-00869-w. Epub 2024 Jun 18. Am J Clin Dermatol. 2024. PMID: 38888681 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources